Literature DB >> 32176142

What Genes Can Tell: A Closer Look at Vestibular Schwannoma.

Ksenia A Aaron1,2, Zarko Manojlovic3, Nathan Tu2, Yili Xu3, Yuxin Jin3, Sharon Chang3, Eric Kwok3, Michelle Webb3, Kyle Hurth4, Rick A Friedman2,5.   

Abstract

OBJECTIVE: Comprehensive molecular profiling of radioresistant and cystic vestibular schwannoma (VS) subtypes. STUDY
DESIGN: Our study utilized whole-exome sequencing (WES), RNA-sequencing (RNAseq), and correlated clinical data from 12 samples (2 samples of solid sporadic subtype, 8 with cystic changes, and 2 previously irradiated).
SETTING: Academic medical center. PATIENTS: Patients diagnosed with VS who required surgical treatment. Inclusion: Cystic and radioresistant tumors matched to age and tumor volume, with solid sporadic VS samples as control; Exclusion: NF-2 patients. INTERVENTION(S): WES using custom probes for copy number analysis. A modified version of the Agilent Human Whole Exome sequencing hybrid capture system was used to process samples. Recurrent variants were identified and compared between groups. Leukocyte-derived DNA was utilized as internal control to reduce false-positives. MAIN OUTCOME MEASURE(S): Analysis of genetic landscape of VS subtypes (naive solid VS, cystic VS, and previously irradiated VS) by performing deep next-generation sequencing.
RESULTS: WES data achieved a mean coverage of 202X and RNAseq generated an average of 74 million total reads. As a group, 25% of samples had 22q loss. Somatic analysis identified previously reported genes and multiple novel mutations across samples. Differential expression analysis of RNAseq data found significantly mutated genes such as COL6A3, CLMP, ART4, Lumican that were shared by both cystic VS and irradiated VS, but not seen in sporadic VS.
CONCLUSIONS: Using WES we were able to demonstrate that cystic and irradiated samples are subtypes of VS with an increased mutation burden and a unique genetic fingerprint. We identified differences between the genomic and molecular profile of cystic VS and radioresistant VS. Our results help advance the understanding of the pathophysiology of these tumor subtypes and suggest possible molecular targets for novel treatment strategies.

Entities:  

Mesh:

Year:  2020        PMID: 32176142     DOI: 10.1097/MAO.0000000000002580

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  4 in total

Review 1.  Understanding the Molecular Mechanism of Vestibular Schwannoma for Hearing Preservation Surgery: Otologists' Perspective from Bedside to Bench.

Authors:  Makoto Hosoya; Takeshi Wakabayashi; Koichiro Wasano; Takanori Nishiyama; Nobuyoshi Tsuzuki; Naoki Oishi
Journal:  Diagnostics (Basel)       Date:  2022-04-21

2.  Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.

Authors:  M Kathryn Leonard; Gemma S Puts; Nidhi Pamidimukkala; Gautam Adhikary; Yili Xu; Eric Kwok; Yuxin Jin; Devin Snyder; Nicolette Matsangos; Marián Novak; Anup Mahurkar; Amol C Shetty; Radomir M Slominski; Edward C De Fabo; Frances P Noonan; Chi-Ping Day; Mohammed Rigi; Andrzej T Slominski; Michelle G Webb; David W Craig; Glenn Merlino; Richard L Eckert; John D Carpten; Zarko Manojlovic; David M Kaetzel
Journal:  Oncogene       Date:  2021-08-25       Impact factor: 9.867

3.  Gamma Knife Radiosurgery does not alter the copy number aberration profile in sporadic vestibular schwannoma.

Authors:  Morten Lund-Johansen; Per-Morten Knappskog; Aril Løge Håvik; Ove Bruland; Dhanushan Dhayalan
Journal:  J Neurooncol       Date:  2020-09-27       Impact factor: 4.130

4.  The SH3PXD2A-HTRA1 fusion transcript is extremely rare in Norwegian sporadic vestibular schwannoma patients.

Authors:  Peter Taule-Sivertsen; Ove Bruland; Aril Løge Håvik; Eirik Bratland; Morten Lund-Johansen; Per Morten Knappskog
Journal:  J Neurooncol       Date:  2021-07-02       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.